HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
50 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
C3
complement C3
Chromosome 19 Β· 19p13.3
NCBI Gene: 718Ensembl: ENSG00000125730.19HGNC: HGNC:1318UniProt: B4DR57
756PubMed Papers
23Diseases
3Drugs
78Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
RESEARCH IMPACT
Highly StudiedVariant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
GO:0005615extracellular exosomeblood microparticleprotein bindingatypical hemolytic-uremic syndrome with C3 anomalycomplement component 3 deficiencyage-related macular degenerationC3 glomerulonephritis
✦AI Summary

C3 (complement component 3) is a central glycoprotein in the complement system that serves multiple critical functions in immune defense and inflammation. C3 is the most abundant complement protein in plasma and is essential to all three complement activation pathways (classical, lectin, and alternative), serving as the convergence point where all pathways merge 1. The protein functions as a multifunctional molecule that interacts with numerous serum proteins, cell surface receptors, and membrane-associated regulatory proteins, playing important roles in immune response, opsonization and phagocytosis of pathogens, and immune complex solubilization 2. C3 is primarily synthesized in the liver but also produced extrahepatically in various tissues including glomerular epithelial cells, mesangial cells, and astrocytes 345. Its expression is regulated by inflammatory mediators, with interferon-gamma enhancing C3 gene expression in glomerular epithelial cells and astroglioma cells 35, while insulin downregulates C3 expression in hepatocytes through PPARΞ³ activation 6. C3 deficiency, caused by various genetic mutations including splicing defects and amino acid substitutions, results in increased susceptibility to infections and immune dysfunction 2. The complement system's main outputs include lytic killing of microbes, release of pro-inflammatory anaphylatoxins, and opsonization of targets 1.

Sources cited
1
C3 is the most abundant complement protein and central to all three activation pathways
PMID: 33962553
2
C3 is multifunctional, interacting with numerous proteins and essential for immune response and pathogen clearance
PMID: 8031472
3
C3 is synthesized by glomerular epithelial cells and upregulated by interferon-gamma
PMID: 8406564
4
C3 is produced by glomerular mesangial cells
PMID: 8370168
5
C3 is constitutively expressed in astrocytes and enhanced by interferon-gamma
PMID: 1601980
6
Insulin downregulates C3 gene expression in hepatocytes through PPARΞ³ activation
PMID: 29550264
7
C3 deficiency is caused by various genetic mutations and results in immune dysfunction
PMID: 8031472
Disease Associationsβ“˜23
atypical hemolytic-uremic syndrome with C3 anomalyOpen Targets
0.80Strong
complement component 3 deficiencyOpen Targets
0.78Strong
age-related macular degenerationOpen Targets
0.66Moderate
C3 glomerulonephritisOpen Targets
0.59Moderate
complement 3 glomerulopathyOpen Targets
0.59Moderate
age related macular degeneration 9Open Targets
0.56Moderate
macular degenerationOpen Targets
0.56Moderate
membranoproliferative glomerulonephritisOpen Targets
0.53Moderate
paroxysmal nocturnal hemoglobinuriaOpen Targets
0.53Moderate
atypical hemolytic-uremic syndromeOpen Targets
0.50Moderate
retinopathyOpen Targets
0.49Moderate
atrophic macular degenerationOpen Targets
0.49Moderate
degeneration of macula and posterior poleOpen Targets
0.48Moderate
dense deposit diseaseOpen Targets
0.47Moderate
Dowling-Degos disease 1Open Targets
0.47Moderate
complement deficiencyOpen Targets
0.46Moderate
eye diseaseOpen Targets
0.45Moderate
wet macular degenerationOpen Targets
0.44Moderate
dry age related macular degenerationOpen Targets
0.43Moderate
COVID-19Open Targets
0.42Moderate
Complement component 3 deficiencyUniProt
Hemolytic uremic syndrome, atypical, 5UniProt
Macular degeneration, age-related, 9UniProt
Pathogenic Variants78
NM_000064.4(C3):c.373dup (p.Leu125fs)Pathogenic
not provided|Atypical hemolytic-uremic syndrome with C3 anomaly;Complement component 3 deficiency;Age related macular degeneration 9
β˜…β˜…β˜†β˜†2026β†’ Residue 125
NM_000064.4(C3):c.4030-2A>GLikely pathogenic
not provided|Complement component 3 deficiency
β˜…β˜…β˜†β˜†2025
NM_000064.4(C3):c.1775G>A (p.Arg592Gln)Pathogenic
Atypical hemolytic-uremic syndrome with C3 anomaly|not provided|Familial Atypical Hemolytic-Uremic Syndrome|Age related macular degeneration 9;Atypical hemolytic-uremic syndrome with C3 anomaly;Complement component 3 deficiency|C3-related disorder|C3 glomerulonephritis;Atypical hemolytic-uremic syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 592
NM_000064.4(C3):c.3470T>C (p.Ile1157Thr)Pathogenic
Atypical hemolytic-uremic syndrome|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 1157
NM_000064.4(C3):c.2290C>T (p.Arg764Ter)Pathogenic
not provided|Age related macular degeneration 9;Atypical hemolytic-uremic syndrome with C3 anomaly;Complement component 3 deficiency|Complement component 3 deficiency
β˜…β˜…β˜†β˜†2025β†’ Residue 764
NM_000064.4(C3):c.481C>T (p.Arg161Trp)Pathogenic
not provided|Atypical hemolytic-uremic syndrome with C3 anomaly|Atypical hemolytic-uremic syndrome;C3 glomerulonephritis
β˜…β˜…β˜†β˜†2025β†’ Residue 161
NM_000064.4(C3):c.3737_3738del (p.Asp1245_Phe1246insTer)Pathogenic
Atypical hemolytic-uremic syndrome with C3 anomaly|not provided|Complement component 3 deficiency
β˜…β˜…β˜†β˜†2025β†’ Residue 1245
NM_000064.4(C3):c.1774C>T (p.Arg592Trp)Likely pathogenic
Familial Atypical Hemolytic-Uremic Syndrome|not provided|C3 glomerulonephritis;Atypical hemolytic-uremic syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 592
NM_000064.4(C3):c.2863+1G>TLikely pathogenic
Atypical hemolytic-uremic syndrome with C3 anomaly;Age related macular degeneration 9;Complement component 3 deficiency|not provided
β˜…β˜…β˜†β˜†2025
NM_000064.4(C3):c.2825_2826del (p.Val942fs)Pathogenic
Atypical hemolytic-uremic syndrome with C3 anomaly;Age related macular degeneration 9;Complement component 3 deficiency|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 942
NM_000064.4(C3):c.3154+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_000064.4(C3):c.1005_1015delPathogenic
Complement component 3 deficiency
β˜…β˜†β˜†β˜†2025
NM_000064.4(C3):c.2542C>T (p.Arg848Ter)Pathogenic
Complement component 3 deficiency
β˜…β˜†β˜†β˜†2025β†’ Residue 848
NM_000064.4(C3):c.4631-2A>GLikely pathogenic
C3 DEFICIENCY|Complement component 3 deficiency
β˜…β˜†β˜†β˜†2025
NM_000064.4(C3):c.3100T>A (p.Trp1034Arg)Likely pathogenic
Atypical hemolytic-uremic syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 1034
NM_000064.4(C3):c.3100T>C (p.Trp1034Arg)Likely pathogenic
Atypical hemolytic-uremic syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 1034
NM_000064.4(C3):c.3281C>A (p.Ala1094Asp)Likely pathogenic
Atypical hemolytic-uremic syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 1094
NM_000064.4(C3):c.3346G>C (p.Gly1116Arg)Likely pathogenic
Atypical hemolytic-uremic syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 1116
NM_000064.4(C3):c.1269+5G>ALikely pathogenic
Complement component 3 deficiency
β˜…β˜†β˜†β˜†2025
NM_000064.4(C3):c.2768_2773del (p.Asp923_Gly924del)Likely pathogenic
C3 glomerulonephritis
β˜…β˜†β˜†β˜†2025β†’ Residue 923
View on ClinVar β†—
Drug Targets3
AL-78898APhase II
Complement C3 inhibitor
macular degeneration
AMY-101Phase II
Complement C3 inhibitor
gingivitis
PEGCETACOPLANApproved
Complement C3 inhibitor
Related Genes
CFPProtein interaction100%CR1Protein interaction100%CD46Protein interaction100%CFIProtein interaction100%CFHR1Protein interaction100%ITGAMProtein interaction100%
Tissue Expression6 tissues
Liver
100%
Lung
5%
Ovary
4%
Heart
4%
Brain
1%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
C3CFPCR1CD46CFICFHR1ITGAM
PROTEIN STRUCTURE
Preparing viewer…
PDB2WY7 Β· 1.70 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.54Moderately Constrained
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.46 [0.39–0.54]
RankingsWhere C3 stands among ~20K protein-coding genes
  • #271of 20,598
    Most Researched756 Β· top 5%
  • #724of 1,025
    FDA-Approved Drug Targets1
  • #943of 5,498
    Most Pathogenic Variants78 Β· top quartile
  • #3,419of 17,882
    Most Constrained (LOEUF)0.54 Β· top quartile
Genes detectedC3
Sources retrieved50 papers
Response timeβ€”
πŸ“„ Sources
50β–Ό
1
Structure and expression of the C3 gene.
PMID: 6356427
Springer Semin Immunopathol Β· 1983
1.00
2
Complement C3 deficiency: human, animal, and experimental models.
PMID: 8031472
Pathobiology Β· 1994
0.90
3
Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction.
PMID: 37105991
Nat Commun Β· 2023
0.82
4
Purification and characterization of human and mouse complement C3.
PMID: 24218251
Methods Mol Biol Β· 2014
0.80
5
Human complement component C3: cDNA coding sequence and derived primary structure.
PMID: 2579379
Proc Natl Acad Sci U S A Β· 1985
0.80